Annexon Inc stock is traded at $4.01, with a volume of 4,359,974. It is down -7.51% in the last 24 hours and down -0.62% over the past month. Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Previous Close:
$4.33
Open:
$4.29
24h Volume:
4,359,974
Relative Volume:
1.29
Market Cap:
$759.26M
Revenue:
-
Net Income/Loss:
-$196.48M
P/E Ratio:
-
EPS:
-$1.22
Net Cash Flow:
-$183.16M
1W Performance:
-1.11%
1M Performance:
-0.62%
6M Performance:
-29.74%
1Y Performance:
+32.62%
1-Day Range:
$0.00$0.00
1-Week Range:
$3.83$4.52
52-Week Range:
$2.54$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon IncSector
HealthcareIndustry
BiotechnologyPhone
(650) 822-5500Address
1400 SIERRA POINT PARKWAY, BRISBANE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS